PARP16 and Parkinson disease: Specifically, CCNE1 significantly upregulates the expression of PARP16 (β1 = 0.318, p = 2.36 × 10−18), while PARP16 itself shows a significant negative correlation with PD risk (β2 = −0.503, p = 5.8 × 10−4), which reveals the potential molecular pathway of CCNE1‐PARP16‐PD.